Earnings Feed
Start Free
Home/Filings/4/0001415889-24-024044
4//SEC Filing

HEALY JAMES 4

Accession 0001415889-24-024044

CIK 0001709941other
View on SEC.govCompany Profile

Filed

Sep 26, 8:00 PM ET

Accepted

Sep 27, 4:22 PM ET

Size

20.3 KB

Accession

0001415889-24-024044

Insider Transaction Report

Form 4
Period: 2024-09-25
BioAge Labs, Inc.BIOA
HEALY JAMES
Director
Transactions
  • Purchase

    Common Stock

    2024-09-27$18.00/sh+11,113$200,034→ 11,113 total(indirect: Sofinnova Synergy Master Fund LP)
  • Conversion

    Common Stock

    2024-09-27+1,638,236→ 1,638,236 total(indirect: Sofinnova Venture Partners XI, L.P.)
  • Purchase

    Common Stock

    2024-09-27$18.00/sh+21,814$392,652→ 21,814 total(indirect: Crestline Summit Master, SPC - PEAK SP)
  • Purchase

    Common Stock

    2024-09-27$18.00/sh+26,497$476,946→ 26,497 total(indirect: CRESTLINE SUMMIT PINNACLE MASTER, L.P.)
  • Conversion

    Series D Preferred Stock

    2024-09-27−7,310,796→ 0 total(indirect: Sofinnova Venture Partners XI, L.P.)
    → Common Stock (1,638,236 underlying)
  • Award

    Stock Option (Right to Buy)

    2024-09-25+15,000→ 15,000 total
    Exercise: $18.00Exp: 2034-09-24→ Common Stock (15,000 underlying)
  • Purchase

    Common Stock

    2024-09-27$18.00/sh+588,888$10,599,984→ 2,227,124 total(indirect: Sofinnova Venture Partners XI, L.P.)
  • Purchase

    Common Stock

    2024-09-27$18.00/sh+18,353$330,354→ 18,353 total(indirect: CRESTLINE SUMMIT MASTER, SPC - CRESTLINE SUMMIT APEX SP)
Footnotes (9)
  • [F1]Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614. The securities have no expiration date.
  • [F2]These shares are directly held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP") is the general partner of SVP XI, and Sofinnova Management XI, L.L.C. ("SM XI") is the general partner of SM XI LP. The reporting person is a managing member of SM XI and may be deemed to share voting and investment discretion with respect to securities directly held by SVP XI.
  • [F3]The reporting person disclaims beneficial ownership of the securities directly held by each of: (i) SVP XI; (ii) Synergy Fund; (iii) APEX SP; (iv) PEAK SP; and (v) Pinnacle LP. This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any.
  • [F4]Represents shares purchased from the Issuer in a private placement transaction.
  • [F5]These shares are directly held by Sofinnova Synergy Master Fund LP ("Synergy Fund"). Sofinnova Synergy GP, LLC ("Synergy Fund GP") is the general partner of Synergy Fund. The reporting person is a managing member of Synergy Fund GP and may be deemed to share voting and investment discretion with respect to securities directly held by Synergy Fund.
  • [F6]These shares are directly held by Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP ("APEX SP"). Synergy Fund GP is the general partner of APEX SP. The reporting person is a managing member of Synergy Fund GP and may be deemed to share voting and investment discretion with respect to securities directly held by APEX SP.
  • [F7]The shares are directly held by Crestline Summit Master, SPC - PEAK SP ("PEAK SP"). Synergy Fund GP is the general partner of PEAK SP. The reporting person is a managing member of Synergy Fund GP and may be deemed to share voting and investment discretion with respect to securities directly held by PEAK SP.
  • [F8]The shares are directly held by CRESTLINE SUMMIT PINNACLE MASTER, L.P. ("Pinnacle LP"). Synergy Fund GP is the general partner of Pinnacle LP. The reporting person is a managing member of Synergy Fund GP and may be deemed to share voting and investment discretion with respect to securities directly held by Pinnacle LP.
  • [F9]The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

Documents

1 file

Issuer

BioAge Labs, Inc.

CIK 0001709941

→
Entity typeother

Related Parties

1
  • filerCIK 0001245624

Filing Metadata

Form type
4
Filed
Sep 26, 8:00 PM ET
Accepted
Sep 27, 4:22 PM ET
Size
20.3 KB
View on SEC.gov